MedTrace Logo

Oral Colchicine in Men With Castrate Resistant Prostate Cancer

NCT01481233 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-09-27

No results posted yet for this study

Summary

The purpose of this study is to determine the prostate specific antigen response to continuous low dose oral colchicine.

Conditions

Interventions

DRUG

Colchicine

Colchicine 0.6 mg bid to a maximum of 1.2 mg bid

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Joseph J Drabick, MD · Milton S. Hershey Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2013-08-31
Completion
2013-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01481233 on ClinicalTrials.gov